Join/Watch the weekly
TMAU UP Podcasts

MEBO Private Facebook Group
to join : contact
maria.delatorre@meboresearch.org

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact map@meboresearch.org

MEBO TMAU urine test

MEBO Research
TMAU Urine Test
United States only
PROGRAM IS PERMANENTLY SUSPENDED AS OF 2 MAY 2017

Click here for
REQUISITION FORM
Incomplete applications
will NOT be processed

SEE UPDATES HERE

1
test
$150 plus
shipping costs
2
tests
$250 plus
shipping costs

TWO PAYMENT PLAN OPTION
Send email to maria.delatorre@meboresearch.org to arrange, AFTER filling out Requisition Form, please.

Test analysis performed in batches of 20 or more

DATE: 2 MAY 2017
Currently on : PROGRAM IS TEMPORARILY SUSPENDED

Samples analyzed since June 2012 :
352
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect
BannerFans.com
RESEARCH DETAILS

DONATIONS THRU 31-NOV-2016:
£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14

MEBO UK PAYPAL FOR TRINZYME

********
MEBO US PAYPAL FOR TRINZYME

Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Thursday, March 8, 2012

ADVOCACY ALERT for NORD Member Organizations




Please support this Bill by writing to your legislator asking them to support it.

H.R. 4132, Faster Access to Specialized Treatments or the FAST Act intends to
  1. Speed the approval of new therapies for patients with serious and life-threatening diseases while also maintaining FDA's high standards for safety and efficacy,
  2. provides further clarity of the FDA approval process by codifying and modernizing the well-established Accelerated Approval program
  3. Enhance and expand the Accelerated Approval process with additional provisions to promote development of treatments for unmet medical needs.

Please write to President Obama here : http://www.whitehouse.gov/CONTACT/
Write to your senator : http://www.senate.gov/general/contact_information/senators_cfm.cfm
Write to your House Representative : http://www.house.gov/representatives/
and ask them to "support H.R. 4132, Faster Access to Specialized Treatments or the FAST Act"


For NORD Member Organizations

» » » ADVOCACY ALERT « « «

NORD Supports FAST Act Introduced by Representatives Stearns and Towns

Bill to Expedite Development of Therapies for Patients with Unmet Medical Needs

WASHINGTON DC-----The National Organization for Rare Disorders (NORD) supports proposed legislation introduced this week by Representatives Cliff Stearns (R-FL) and Edolphus (Ed) Towns (D-NY) to accelerate the development of innovative therapies for people with serious or life-threatening diseases.

H.R. 4132, Faster Access to Specialized Treatments or the FAST Act, is designed to modernize and expand the Food and Drug Administration's Accelerated Approval pathway to encompass a broader range of diseases and encourage innovative drug development tools and strategies.

"We applaud Representatives Stearns and Towns for their leadership in introducing this much-needed legislation," said NORD President and CEO Peter L. Saltonstall. "There are millions of Americans with rare diseases who have no FDA-approved treatment. Accelerating the development of safe, effective therapies for these patients is a top priority for the rare disease community."

Saltonstall said Stearns and Towns have listened to the concerns of patients and have responded with legislation that will speed the approval of new therapies for patients with serious and life-threatening diseases, while also maintaining FDA's high standards for safety and efficacy. He said the bill also provides further clarity of the FDA approval process by codifying and modernizing the well-established Accelerated Approval program.

NORD also supports legislation introduced by Senator Kay Hagan (D-NC) in the U.S. Senate recently known as the TREAT Act. The Senate bill also is intended to enhance and expand the Accelerated Approval process, with additional provisions to promote development of treatments for unmet medical needs.

"Accelerated Approval" refers to a pathway at FDA that allows for earlier approval of drugs for serious, unmet medical need based on a surrogate endpoint or marker predicting clinical benefit. Subsequent testing must be done to verify the anticipated benefit.

Of the approximately 7,000 rare diseases, only about 250 currently have treatments approved by FDA. In the U.S., a disease is considered rare if it affects fewer than 200,000 Americans.

NORD represents the nearly 30 million Americans who have rare diseases. More than half of these patients are children, and most rare diseases are serious, life-altering or even life-threatening diseases.

Thank you for your support!

María

María de la Torre
Founder and Executive Director

A Public Charity
www.meboresearch.org
www.brasil.meboresearch.org
maria.delatorre@meboresearch.org
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)



SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.


Please use your credit card to make your donation to MEBO.


Subscribe for latest posts : Enter your email address:

Delivered by FeedBurner


A EURORDIS and NORD Member Organization

0 comments:

Post a Comment